PT-141 — Technical Research Profile

Molecular and structural context

PT-141, or bremelanotide, is a conformationally constrained cyclic heptapeptide derived from melanocortin peptide pharmacology. Cyclization and non-natural residues increase proteolytic stability and shape receptor-subtype activity.

Mechanistic research framework

Melanocortin receptors are class A GPCRs that commonly stimulate cAMP through Gs. PT-141 research often focuses on MC3R/MC4R potency, receptor selectivity, central signalling, internalization, and potential pathway bias.

Laboratory work examines melanocortin-receptor engagement, central signalling pathways, ligand selectivity, and concentration-response relationships.

Experimental applications and endpoint selection

Recommended mechanistic designs include receptor-subtype panels, cAMP assays, beta-arrestin recruitment, binding competition, receptor internalization, and concentration-response comparison with alpha-MSH or related cyclic analogues.

This material is intended for analytical, biochemical, receptor-pharmacology, cellular, or other controlled preclinical workflows as appropriate to the target system. Study design should define the biological matrix, exposure duration, concentration range, replicate structure, acceptance criteria, and statistical plan before data collection.

Principal areas of scientific inquiry

• Melanocortin receptor pharmacology
• Central signalling models
• Ligand selectivity and dose-response studies

Technical keywords

• MC3R/MC4R pharmacology
• Cyclic peptide
• cAMP signalling
• Receptor selectivity

Analytical characterization considerations

Cyclic integrity, stereochemistry, oxidation, and terminal modifications can influence potency. LC-MS, RP-HPLC, and subtype-specific functional assays provide complementary evidence of chemical and pharmacological identity.

Where scientifically appropriate, laboratories may use orthogonal methods such as reversed-phase HPLC for chromatographic purity, LC-MS for molecular identity, size-sensitive methods for aggregation, and a target-relevant functional assay for biological activity. Method suitability, reference standards, system suitability, and acceptance limits must be independently established; these examples are not batch-specific analytical claims.

Study design and interpretation

Use vehicle, positive, negative, and concentration-matched controls appropriate to the assay. Receptor expression, biological matrix, incubation time, adsorption, proteolysis, passage number, and species background can all change apparent potency or pathway output. Observations from in vitro or animal models should not be extrapolated to human use.

Handling and documentation

Use calibrated equipment and documented receipt, storage, preparation, aliquoting, freeze-thaw, and disposal procedures. Solvent compatibility, working concentration, stability window, container adsorption, and assay recovery must be established by the purchasing laboratory using the applicable batch documentation and institutional standard operating procedures.

Important compliance and safety remarks

• No therapeutic, diagnostic, cosmetic, or veterinary claims are made.
• Work must be performed by qualified personnel under applicable institutional and regulatory requirements.
• Use appropriate personal protective equipment and controlled laboratory procedures.

For research use only. Not for human or animal consumption.